Tue, February 19, 2013
Mon, February 18, 2013

Christopher Raymond Maintained (BMRN) at Buy with Increased Target to $64 on, Feb 19th, 2013

Christopher Raymond of Piper Sandler, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $55 to $64 on, Feb 19th, 2013.

Christopher has made no other calls on BMRN in the last 4 months.



There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 0 agree with Christopher's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Christopher


  • Michelle Gilson of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $71 on, Tuesday, February 12th, 2013
  • Martin Auster of "UBS" Maintained at Strong Buy with Increased Target to $67 on, Friday, February 1st, 2013
  • Gena Wang of "Barclays" Maintained at Buy with Increased Target to $54 on, Tuesday, November 6th, 2012